Constitution Day Conversation about Civility, Diversity, and Inclusion

In this Constitution Day event, Dr. Sharika Thiranagama (Sakurako and William Fisher Family Faculty Scholar in the School of Humanities and Sciences and assistant professor of anthropology at Stanford University) and Dr. Brandon Turner (associate professor of political science at Clemson University) discuss the relationship between civility, diversity, and inclusion with Linfield College students Pedro Graterol and Aspen Brooks. Each panelist delivers a short speech on the topic, followed by a conversation among the speakers

Facilitating a more efficient commercial review process for pediatric drugs and biologics

Over the past two decades, the biopharmaceutical industry has seen unprecedented expansion and innovation in concert with significant technological advancements. While the industry has experienced marked growth, the regulatory system in the United States still operates at a capacity much lower than the influx of new drug and biologic candidates. As a result, it has become standard for months or even years of waiting for commercial approval by the U.S. Food and Drug Administration. These regulatory delays have generated a system that stifles growth and innovation due to the exorbitant costs associated with awaiting approval from the nation’s sole regulatory agency. The recent re-emergence of diseases that impact pediatric demographics represents one particularly acute reason for developing a regulatory system that facilitates a more efficient commercial review process. Herein, we present a range of initiatives that could represent early steps toward alleviating the delays in approving life-saving therapeutics

Predictors of psychological outcome in patients with eating disorders: A routine outcome monitoring study

Stress-related psychiatric disorders across the life spa